• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Combination chemotherapy using cyclophosphamide, adriamycin, and cisplatin in recurrent or advanced endometrial cancer--a preliminary report].

作者信息

Baba S, Kashimura M, Shinohara M, Kusano S, Sasayama T, Hamasaki K

机构信息

Dept. of Obstet. & Gyne., School of Med., Univ. of Occupational and Environmental Health.

出版信息

Gan No Rinsho. 1989 Feb;35(3):371-7.

PMID:2926985
Abstract

Four patients with recurrent or advanced endometrial cancer have undergone combination chemotherapy with Cyclophosphamide, Adriamycin and Cisplatin (CAP). All drugs were administered by I.V. on day 1 in the following doses: Cyclophosphamide 500 mg/m2, Adriamycin 50 mg/m2 and Cisplatin 50 mg/m2. The treatment was repeated every 4 weeks and continued as long as there was disease progression. Two complete clinical responses and two partial responses were achieved. Based on these good results, we have initiated post-operative prophylactic chemotherapy using CAP in high risk patients. Adverse effects including myelo-suppression, nausea, and vomiting, and alopecia were seen in almost all patients. In no case, however, did any patient experience life-threatening toxicity. Based on our experience, CAP therapy appears tolerable when used per our schedule.

摘要

相似文献

1
[Combination chemotherapy using cyclophosphamide, adriamycin, and cisplatin in recurrent or advanced endometrial cancer--a preliminary report].
Gan No Rinsho. 1989 Feb;35(3):371-7.
2
ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.ICON 2和ICON 3研究中既往未接受治疗的卵巢癌数据:迄今的结果。
Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-23-S15-25.
3
A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.一项关于依达曲沙联合长春碱、阿霉素、顺铂和非格司亭(EVAC/G-CSF)用于晚期恶性肿瘤患者的剂量探索性试验:对非小细胞肺癌具有有前景的抗肿瘤活性。
Cancer J Sci Am. 1997 Sep-Oct;3(5):297-302.
4
Use of cisplatin, doxorubicin, and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium.
Cancer Treat Rep. 1986 Jun;70(6):789-91.
5
[Combination therapy with etoposide, adriamycin and cisplatin in advanced primary and recurrent gastric cancer].
Gan To Kagaku Ryoho. 1989 Dec;16(12):3713-8.
6
[The immediate results of the combined chemotherapy of disseminated forms and recurrences of cervix uteri cancer with vincristine, platidiam and adriamycin].
Vopr Onkol. 1991;37(11-12):1090-4.
7
[Combination chemotherapy of cyclophosphamide, adriamycin and cisplatin in advanced urothelial cancer].
Gan To Kagaku Ryoho. 1987 Nov;14(11):3071-7.
8
Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.中高危子宫内膜癌患者盆腔放疗与铂类联合化疗的随机 III 期试验:日本妇科肿瘤学组研究
Gynecol Oncol. 2008 Jan;108(1):226-33. doi: 10.1016/j.ygyno.2007.09.029. Epub 2007 Nov 9.
9
Doxorubicin and cyclophosphamide chemotherapy for disseminated endometrial cancer.
Obstet Gynecol. 1981 Jul;58(1):88-91.
10
[Combination chemotherapy with cyclophosphamide, adriamycin, cisplatin, nimustine(ACNU), and methotrexate (EACAM) in advanced adenocarcinoma of the lung].
Gan To Kagaku Ryoho. 1985 Jun;12(6):1339-44.